Search Results for: AC Immune SA to Receive
Articles
GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 28, 2023
GeoVax Labs, Inc. recently announced the US Patent and Trademark Office has issued a Notice of Allowance for Patent Application...Vaxxas Opens World-Class Manufacturing Facility to Produce Proprietary Needle-Free Vaccine Patch For Late-Stage Clinical Trials & First Commercial Products August 24, 2023
Vaxxas recently announced the opening of its first, state-of-the-art manufacturing facility in Brisbane, Queensland. The custom-built 60,000-sq-ft Vaxxas Biomedical Facility will serve as….
GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients With Chronic Lymphocytic Leukemia August 10, 2023
GeoVax Labs, Inc. recently announced vaccinations have begun in an investigator-initiated clinical trial (ClinicalTrials.gov Identifier: NCT05672355) of GEO-CM04S1 in patients...Tonix Pharmaceuticals Announces Initiation of Enrollment in MGH Phase 2 POWER Study of Intranasal Potentiated Oxytocin for the Treatment of Pediatric Obesity July 10, 2023
Tonix Pharmaceuticals Holding Corp. recently announced the first participant was enrolled in the Phase 2 POWER study of TNX-1900 (intranasal...Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation From EMA for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation July 6, 2023
Akari Therapeutics, Plc recently announced the European Medicines Agency (EMA) has issued a positive opinion on the company’s application for...ASLAN Pharmaceuticals Enters Strategic Licensing Deal With Zenyaku Kogyo for the Development & Commercialization of Eblasakimab June 22, 2023
ASLAN Pharmaceuticals and Zenyaku Kogyo Co., Ltd., a subsidiary of privately held Zenyaku Holdings Co., Ltd. recently announced a strategic...PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 & KEYTRUDA in Head & Neck Cancer June 14, 2023
PDS Biotechnology Corporation recently announced it achieved the threshold for efficacy as per investigator assessment in Stage 2 of the...Mustang Bio Announces Updated Results From Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy June 12, 2023
Mustang Bio, Inc. recently announced that updated data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous...Quell Therapeutics Signs Collaboration, Exclusive Option & License Agreement With AstraZeneca to Develop, Manufacture & Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases June 9, 2023
Collaboration brings together Quell’s proprietary multi-modular T-regulatory (Treg) cell engineering and manufacturing expertise with AstraZeneca’s proven development and commercial capabilities as well as its deep therapeutic area knowledge….
ANTI-VIRAL RESEARCH - Anti-Viral Activity of Pimpinella anisum Extract In Vitro Study June 5, 2023
Fouad Al-Bayaty, Mazen M. Jamil Al-Obaidi, Maryam Haki Al-Doori, and Omar Imad present a study conducted to evaluate the antiviral effectiveness of Pimpinella anisum against dengue virus.
Positive Phase 2 Data of Novel Investigational Anti-CD40L Antibody Frexalimab Show Significantly Reduced Disease Activity in Relapsing Multiple Sclerosis May 31, 2023
New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, demonstrate...MetrioPharm Receives Orphan Drug Designation for the Treatment of Duchenne Muscular Dystrophy May 30, 2023
MetrioPharm AG recently announced the US FDA has granted Orphan Drug Designation for MP1032 for the treatment of Duchenne muscular...BriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp. May 25, 2023
BriaCell Therapeutics Corp. recently announce it has entered into an arrangement agreement dated May 24, 2023, with BriaPro Therapeutics Corp....Pyxis Oncology to Acquire Apexigen May 24, 2023
Pyxis Oncology, Inc. and Apexigen, Inc. recently announced a definitive agreement by which Pyxis Oncology will acquire Apexigen in an all-stock transaction for an implied value of….
Biodexa Pharmaceuticals Enters Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals May 18, 2023
Biodexa Pharmaceuticals recently announced it has signed non-binding letter of intent to potentially acquire Varian Biopharmaceuticals, Inc., a private US precision oncology company developing….
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha & Anti-PD-L1 Therapy May 1, 2023
Immutep Limited recently announced it has received regulatory approval from the Paul-Ehrlich-Institut (PEI), German Federal Institute for Vaccines and Biomedicines,...Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab April 25, 2023
Vaccinex, Inc. recently announced it has completed enrollment goal in the SIGNAL-AD clinical trial for people with mild dementia due...Tiziana Life Sciences to Proceed With Phase 2 Clinical Trial in Patients With Non-Active Secondary Progressive Multiple Sclerosis March 28, 2023
Tiziana Life Sciences Ltd. recently announced it has received feedback based on the US FDA Type C meeting minutes related to the Phase 2 clinical trial of intranasal foralumab in patients with non-active SPMS…..
Vaccitech Announces Positive Topline Final Data for HBV002 Study in People With Chronic Hepatitis B March 28, 2023
Vaccitech plc recently announced positive topline final data from the HBV002 study (NCT04778904), a Phase 1b/2a clinical trial of VTP-300...Jounce Therapeutics to be Acquired by Concentra Biosciences March 27, 2023
Jounce Therapeutics, Inc. recently announced it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC (Concentra) will acquire Jounce for $1.85 in cash per share plus….
